JUSTICE Clinical Trial Janus kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease (JUSTICE)

JUSTICE is a single-center, double-blinded, randomized trial of baricitinib therapy for APOL1-associated FSGS or Hypertension Associated-CKD.

You may be eligible to participate in JUSTICE clinical trial If you meet the following criteria:

  • Self-identified African American/Black
  • Adults 18-70 years
  • APOL1 genotype of G1G1, G1G2, or G2G2
  • FSGS diagnosed by kidney biopsy or clinically diagnosed HTN-CKD
  • Urine albumin ≥300 mg/g
  • Estimated glomerular filtration rate (eGFR) ≥30 ml/min/1.73 m2
  • Able to provide written informed consent

WHAT TO EXPECT IF YOU PARTICIPATE IN JUSTICE TRIAL:

  • Participants will be randomized to receive baricitinib or placebo control.
  • Urine and a small blood sample will be collected monthly to monitor kidney function. Participants will be followed for 6 months.
  • Participants will receive gift cards each month.

Study Drug is provided by Eli Lilly.

JOIN US TO DISCOVER A CURE FOR APOL1-MEDIATED KIDNEY DISEASE

Contact us to see if you are eligible to participate in JUSTICE ClinicalTrial

[contact-form-7 id=”80″]